Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johanna Oechtering

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Journal of Neurology|July 2, 2025
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis CohortAlessandro Cagol, Sabine Schaedelin, Mario Ocampo-Pineda, et al.
JAMA Neurology|November 6, 2023
Neurofilament Light Chain Elevation and Disability Progression in Multiple SclerosisAhmed Abdelhak, Pascal Benkert, Sabine Schaedelin, et al.
Annals of Neurology|May 31, 2021
Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple SclerosisJohanna Oechtering, Sabine Schaedelin, Pascal Benkert, et al.
JAMA Neurology|February 6, 2023
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple SclerosisStephanie Meier, Eline A J Willemse, Sabine Schaedelin, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 3, 2025
Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple SclerosisJohanna Oechtering, Sabine Anna Schaedelin, Kerstin Stein, et al.
Annals of Clinical and Translational Neurology|August 4, 2025
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment ResponseMaximilian Einsiedler, Aleksandra Maleska Maceski, Sofia Sandgren, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 29, 2025
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi StudyÖzgür Yaldizli, Pascal Benkert, Lutz Achtnichts, et al.
Brain : a Journal of Neurology|November 14, 2025
GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosisAleksandra Maleska Maceski, Pascal Benkert, Maximilian Einsiedler, et al.
Neurology|January 2, 2024
Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MSAlessandro Cagol, Pascal Benkert, Lester Melie-Garcia, et al.
JAMA Neurology|May 16, 2022
Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple SclerosisAlessandro Cagol, Sabine Schaedelin, Muhamed Barakovic, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Journal of Neurology|July 2, 2025
Comparative effectiveness of teriflunomide and ocrelizumab on smoldering activity in multiple sclerosis: an observational study in the Swiss Multiple Sclerosis CohortAlessandro Cagol, Sabine Schaedelin, Mario Ocampo-Pineda, et al.
JAMA Neurology|November 6, 2023
Neurofilament Light Chain Elevation and Disability Progression in Multiple SclerosisAhmed Abdelhak, Pascal Benkert, Sabine Schaedelin, et al.
Annals of Neurology|May 31, 2021
Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple SclerosisJohanna Oechtering, Sabine Schaedelin, Pascal Benkert, et al.
JAMA Neurology|February 6, 2023
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple SclerosisStephanie Meier, Eline A J Willemse, Sabine Schaedelin, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|January 3, 2025
Aberrant Complement Activation Is Associated With Structural Brain Damage in Multiple SclerosisJohanna Oechtering, Sabine Anna Schaedelin, Kerstin Stein, et al.
Annals of Clinical and Translational Neurology|August 4, 2025
Serum Neurofilament Light Chain in Multiple Sclerosis: Superiority of Age- and BMI-Corrected Z Scores/Percentiles Over Absolute Cutoff Values for Prediction of Treatment ResponseMaximilian Einsiedler, Aleksandra Maleska Maceski, Sofia Sandgren, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 29, 2025
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi StudyÖzgür Yaldizli, Pascal Benkert, Lutz Achtnichts, et al.
Brain : a Journal of Neurology|November 14, 2025
GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosisAleksandra Maleska Maceski, Pascal Benkert, Maximilian Einsiedler, et al.
Neurology|January 2, 2024
Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MSAlessandro Cagol, Pascal Benkert, Lester Melie-Garcia, et al.
JAMA Neurology|May 16, 2022
Association of Brain Atrophy With Disease Progression Independent of Relapse Activity in Patients With Relapsing Multiple SclerosisAlessandro Cagol, Sabine Schaedelin, Muhamed Barakovic, et al.
Pageof 6